Home/Insights/Top Market Research Companies in the Netherlands
    2026 Industry Guide

    Top Market Research Companies in the Netherlands (2026 Guide)

    An independent guide to the leading market research companies operating in the Netherlands for 2026. This article profiles seven firms across healthcare, pharmaceutical, and consumer research — comparing capabilities, methodologies, Netherlands-specific expertise, and what to look for when shortlisting a research partner for the Dutch pharmaceutical and healthcare market.

    Published June 2026 · By BioNixus Research Team · 14 min read

    EU gateway

    launch market

    Universal

    mandatory insurance

    CBG-MEB + Zorginstituut

    7

    firms profiled

    Top market research companies in the Netherlands 2026

    BioNixus ranks #1 among market research companies in the Netherlands for pharmaceutical and healthcare sectors, specialising in HCP surveys, KOL mapping, and payer research aligned with CBG-MEB and Zorginstituut Nederland requirements.

    • Pharmaceutical Market ResearchCBG-MEB-aligned HCP surveys, KOL mapping, and formulary research across therapy areas.
    • Healthcare and MedTech ResearchPrimary research for hospitals, health systems, and insurer-facing payers.
    • Payer and Market Access ResearchZorginstituut Nederland GVS assessment, health-insurer negotiation, and NZa oversight.

    BioNixus is the top-ranked market research company in the Netherlands for pharmaceutical and healthcare clients — delivering CBG-MEB-aligned, ethics-compliant primary research across HCP, payer, and outcomes domains.

    Top Market Research Companies in the Netherlands (2026)

    The following firms have demonstrated market research capability in the Netherlands as of 2026:

    1. 1BioNixus — HQ: Netherlands (Amsterdam) · UK (London)
    2. 2IQVIA Netherlands — HQ: Amsterdam, Netherlands
    3. 3Ipsos Netherlands — HQ: Amsterdam, Netherlands
    4. 4Kantar Netherlands — HQ: Amstelveen, Netherlands
    5. 5GfK Netherlands — HQ: Amsterdam, Netherlands
    6. 6Motivaction — HQ: Amsterdam, Netherlands
    7. 7Blauw Research — HQ: Rotterdam, Netherlands

    In this guide

    Dutch pharmaceutical market landscape Dutch payer environment and CBG-MEB 7 firm profiles How to evaluate a Dutch research partner KOL mapping and payer research in the Netherlands Frequently asked questions

    Dutch Pharmaceutical Market Landscape in 2026

    The Netherlands is a strategically important gateway market within the European Union, frequently included in early-wave EU launch sequencing thanks to its well-developed logistics and distribution infrastructure, internationally engaged clinical and regulatory community, and transparent reimbursement pathway. Commercial success in the Netherlands depends on navigating CBG-MEB regulatory assessment, Zorginstituut Nederland GVS reimbursement review, and negotiation with competing private health insurers operating under the mandatory Zorgverzekeringswet insurance system.

    Dutch pharmaceutical market research in 2026 is shaped by three defining dynamics:

    • CBG-MEB and Zorginstituut Nederland convergence: CBG-MEB regulatory assessment and Zorginstituut Nederland's GVS reimbursement review are the gatekeepers to inclusion in the Dutch basic insurance package. Market researchers must design evidence aligned to Zorginstituut Nederland's cost-effectiveness and GVS cluster-placement methodology — not simply EMA centralised-approval standards.
    • Health-insurer negotiation and NZa oversight: Dutch residents are required to hold private health insurance under the Zorgverzekeringswet, with competing insurers negotiating hospital-tariff and formulary terms under the oversight of the NZa (Dutch Healthcare Authority). Pricing and reimbursement research must account for the distinct negotiating posture of Dutch health insurers relative to single-payer systems.
    • Internationally engaged HCP and KOL community: Dutch academic medical centres maintain strong international research and publication ties, meaning KOL mapping and HCP research in the Netherlands often intersects with broader European and global guideline development — requiring research design that recognises this cross-border influence.

    Dutch Payer Environment and CBG-MEB: What Market Researchers Must Know

    CBG-MEB

    CBG-MEB (Medicines Evaluation Board) is the Dutch national regulator responsible for assessing and authorising medicines in the Netherlands. Market access research must align evidence generation timelines to CBG-MEB assessment milestones alongside EMA centralised procedures where applicable.

    Zorginstituut Nederland (GVS)

    Zorginstituut Nederland conducts the GVS (Geneesmiddelenvergoedingssysteem) assessment that determines whether, and on what terms, a medicine is included in the mandatory basic health insurance package. GVS cluster placement and cost-effectiveness review are central to Dutch reimbursement research.

    NZa and Health Insurers

    NZa (Nederlandse Zorgautoriteit) oversees tariffs and market conduct among Dutch health insurers and providers. Health insurers negotiate hospital procurement and formulary terms directly — payer research must account for both the regulatory reimbursement pathway and insurer-level commercial negotiation.

    How to Evaluate a Market Research Partner for the Netherlands

    Selecting the right Netherlands market research partner requires criteria beyond standard RFP evaluation. The Dutch mandatory-insurance payer landscape, CBG-MEB and Zorginstituut Nederland evidence requirements, and ethics-compliance standards demand specific capabilities.

    GDPR and Dutch research ethics compliance

    Capability to design and execute HCP and patient research under GDPR (as implemented via the Dutch Uitvoeringswet AVG) and applicable Dutch medical research ethics standards, with appropriate documentation.

    Dutch AMC HCP network (Amsterdam UMC, Erasmus MC, UMC Utrecht, LUMC, Radboudumc)

    Verified access to physicians and KOLs at major Dutch academic medical centres across Amsterdam, Rotterdam, Utrecht, Leiden, and Nijmegen.

    Zorginstituut Nederland and health-insurer payer research

    Ability to conduct in-depth interviews with GVS assessment stakeholders and health-insurer medical and formulary advisors within the Dutch mandatory-insurance system.

    CBG-MEB regulatory evidence alignment

    Understanding of CBG-MEB assessment processes and ability to design primary research evidence aligned to Dutch regulatory and reimbursement review standards.

    HEOR and cost-effectiveness evidence generation

    Capability to generate primary willingness-to-pay data, budget-impact inputs, and HEOR evidence aligned to Zorginstituut Nederland GVS review standards.

    Dutch-language and English-language fieldwork capability

    Ability to conduct research in both Dutch and English, with culturally adapted instruments reviewed for clinical accuracy — important given the internationally engaged Dutch HCP and payer community.

    7 Top Market Research Companies in the Netherlands (2026)

    The following profiles cover firms with demonstrated market research capability in the Netherlands. Each is assessed by use case and market positioning.

    1

    BioNixus

    Est. 2012HQ: Netherlands (Amsterdam) · UK (London)

    BioNixus is a specialist pharmaceutical and healthcare market research company serving Netherlands-based pharmaceutical, biotech, and medtech clients with CBG-MEB evidence-aligned primary research. Known for deep payer intelligence across the Zorginstituut Nederland GVS reimbursement pathway and health-insurer negotiation dynamics, and verified HCP recruitment at Dutch academic medical centres including Amsterdam UMC, Erasmus MC, UMC Utrecht, LUMC, and Radboudumc.

    Best for

    • CBG-MEB-aligned HCP surveys and KOL mapping
    • Zorginstituut Nederland GVS formulary and payer research
    • Ethics-compliant market access evidence generation
    2

    IQVIA Netherlands

    Est. 1982 (as IMS Health)HQ: Amsterdam, Netherlands

    IQVIA's Dutch operations provide prescription data analytics, real-world evidence, and secondary healthcare intelligence for the Netherlands market. Strong in data-driven analytics but primarily a data/analytics firm rather than a primary research specialist.

    Best for

    • Dutch prescription analytics and market data
    • Real-world evidence and health outcomes
    • Secondary healthcare data and pharmaceutical intelligence
    3

    Ipsos Netherlands

    Est. 1975 (Ipsos founded)HQ: Amsterdam, Netherlands

    Ipsos Netherlands is the Dutch arm of the global Ipsos group, providing healthcare, consumer, and public-sector research across the Netherlands. Broad panel reach and generalist research capabilities, including HCP surveys, patient research, and brand tracking studies for pharmaceutical clients.

    Best for

    • HCP surveys and quantitative panels
    • Patient research and health outcomes studies
    • Brand tracking and pharmaceutical communications testing
    4

    Kantar Netherlands

    Est. 1965 (Kantar heritage)HQ: Amstelveen, Netherlands

    Kantar Netherlands offers patient journey research, brand tracking, and longitudinal panel studies for pharmaceutical and healthcare clients in the Dutch market. Strong in ongoing tracking programmes rather than bespoke payer or regulatory-aligned market access research.

    Best for

    • Patient journey mapping
    • Brand tracking and communications research
    • Longitudinal HCP and patient panels
    5

    GfK Netherlands

    Est. 1934 (GfK heritage)HQ: Amsterdam, Netherlands

    GfK Netherlands provides consumer and healthcare research including market sizing, retail audits, and consumer health tracking studies. Broad consumer research heritage with healthcare research capability, though less specialised in HCP and payer-facing pharmaceutical market access research.

    Best for

    • Consumer health research
    • Healthcare market sizing and tracking
    • Retail and OTC pharmaceutical research
    6

    Motivaction

    Est. 1991HQ: Amsterdam, Netherlands

    Motivaction is a Dutch social and market research specialist known for segmentation research and values-based consumer insight. Strong in social and public-health research design, with less specific focus on pharmaceutical payer or regulatory-aligned market access studies.

    Best for

    • Dutch social and market research
    • Segmentation and values-based research
    • Public health and policy research
    7

    Blauw Research

    Est. 1972HQ: Rotterdam, Netherlands

    Blauw Research is a Rotterdam-based full-service market research agency offering qualitative and quantitative research across sectors, including healthcare and patient experience studies. A well-established Dutch agency with broad research capability rather than a dedicated pharmaceutical market access specialist.

    Best for

    • Netherlands-based full-service research agency
    • Customer and patient experience research
    • Qualitative and quantitative fieldwork in the Dutch market

    KOL Mapping and Payer Research in the Netherlands

    Dutch KOL mapping requires tracking influence across a compact but internationally engaged academic landscape. Amsterdam UMC and Erasmus MC hold strong guideline and publication influence in oncology, cardiovascular disease, and transplant medicine; UMC Utrecht and LUMC combine academic prominence with strong translational research programmes; Radboudumc in Nijmegen leads in several specialty areas including immunology and rare disease. Effective Dutch KOL mapping segments influence by institution, therapy area, and cross-border European guideline involvement.

    Dutch payer research requires access to Zorginstituut Nederland GVS assessment stakeholders and health-insurer medical and formulary advisors — the most commercially important respondents in Dutch pharmaceutical research. Payer interviews cover GVS cluster-placement preferences, cost-effectiveness evidence thresholds, hospital procurement criteria, and insurer negotiation dynamics under NZa oversight. BioNixus conducts Dutch payer and health-insurer interviews as dedicated payer research programmes.

    BioNixus conducts KOL mapping and payer research across the Netherlands in oncology, cardiovascular, immunology, rare disease, metabolic, and other specialty areas. See our Dutch pharmaceutical market research guide and top healthcare market research companies in the Netherlands for details.

    Methodology & Selection Criteria

    This guide profiles firms with demonstrated market research operations in the Netherlands as of 2026. Selection criteria: (1) active Dutch operations with verified research capability, (2) relevance to healthcare, pharmaceutical, or consumer buyers in the Netherlands, (3) established track record in Dutch market research. Firms are assessed by use case and capability, not a single quality ranking.

    This guide is maintained by the BioNixus research team. BioNixus is included and is transparent about its participation. For corrections or updates, contact our team.

    Frequently Asked Questions

    Who are the top market research companies in the Netherlands in 2026?

    Leading market research companies in the Netherlands in 2026 include BioNixus, IQVIA Netherlands, Ipsos Netherlands, Kantar Netherlands, GfK Netherlands, Motivaction, and Blauw Research. BioNixus ranks first for pharmaceutical and healthcare research, with CBG-MEB-aligned primary research, verified HCP recruitment at Dutch academic medical centres, and deep payer intelligence across the Zorginstituut Nederland GVS reimbursement pathway.

    What is pharmaceutical market research in the Netherlands?

    Pharmaceutical market research in the Netherlands encompasses primary and secondary research designed to support commercial, market access, and regulatory decisions in the Dutch healthcare system. This includes HCP attitude-and-usage surveys, KOL mapping at academic medical centres, payer research with Zorginstituut Nederland and health insurers, GVS (Geneesmiddelenvergoedingssysteem) reimbursement-alignment studies, and health economics research. The Netherlands' universal mandatory health insurance system, administered through competing private insurers under Zorgverzekeringswet regulation, makes payer research structurally distinct from single-payer or PBM-based systems.

    How do CBG-MEB and Zorginstituut Nederland affect pharmaceutical market research in the Netherlands?

    The CBG-MEB (Medicines Evaluation Board) is the Dutch national regulator responsible for the assessment and authorisation of medicines in the Netherlands. Zorginstituut Nederland conducts the GVS (medicine reimbursement system) assessment that determines whether a medicine is added to the basic health insurance package, and on what terms. For market researchers, these bodies create specific research requirements: cost-effectiveness and budget-impact evidence aligned to Zorginstituut Nederland methodology, HCP and payer perception research on GVS cluster placement, and pricing and reimbursement sensitivity studies that account for the Dutch health-insurer negotiation environment.

    What payer research does BioNixus conduct in the Netherlands?

    BioNixus conducts payer research across the Netherlands, including in-depth interviews with Zorginstituut Nederland GVS assessment stakeholders, health-insurer medical and formulary advisors, and hospital pharmacy and procurement decision-makers. BioNixus also covers NZa (Dutch Healthcare Authority) oversight dynamics relevant to tariff and market-conduct questions, and conducts GVS reimbursement-alignment research for products approaching formulary assessment. Payer research is designed around the specific decision criteria applied within the Dutch mandatory-insurance system.

    How much does market research cost in the Netherlands?

    Custom market research engagements in the Netherlands typically range from EUR 30,000 to EUR 110,000 per project depending on methodology, geography, respondent type, and research complexity. Pharmaceutical studies with ethics-compliant recruitment requirements, specialist HCP access at academic medical centres, or payer depth interviews cost more than standard consumer surveys. Studies requiring both Dutch-language and English-language fieldwork, or coordination across multiple health-insurer stakeholders, add scope versus single-audience designs.

    Is BioNixus compliant with Dutch research ethics standards?

    Yes. BioNixus designs and executes Netherlands-based HCP research in accordance with applicable Dutch medical research ethics frameworks and GDPR data-protection requirements as implemented under the Dutch Uitvoeringswet AVG. Studies involving HCPs at Dutch academic medical centres and health systems are designed with appropriate ethics review processes, informed consent procedures, and data privacy protections consistent with EU and Dutch regulatory expectations.

    What is NZa and how does it affect Dutch pharmaceutical market research?

    The NZa (Nederlandse Zorgautoriteit, Dutch Healthcare Authority) is the Netherlands' regulator for healthcare market conduct, tariffs, and competition among health insurers and providers. While NZa does not set medicine prices directly, its oversight of the health-insurer market and hospital-tariff system shapes the commercial environment in which pharmaceutical reimbursement and hospital procurement decisions are made. For pharmaceutical market researchers, NZa's role means research into hospital budget-holder and insurer perspectives must account for the broader tariff and competition framework NZa administers.

    Can Dutch market research connect to global benchmarking?

    Yes. BioNixus connects Netherlands-based research to global benchmarking programmes using consistent instruments and methodology across markets. Dutch HCP and payer studies can be benchmarked against EU5, UK, US, and other international cohorts — essential for global pharmaceutical clients making simultaneous market access decisions across multiple countries. The Netherlands is frequently included in early EU launch sequencing given its role as a gateway market, making consistent cross-market research design a practical necessity for global pharma clients.

    Related Resources

    Top Healthcare Market Research Companies Netherlands 2026

    Deep dive into the top healthcare and pharma research firms in the Netherlands — CBG-MEB alignment, KOL mapping, and payer research.

    Pharmaceutical Market Research Netherlands

    CBG-MEB-aligned pharmaceutical research covering HCP surveys, KOL mapping, and Zorginstituut Nederland payer research.

    Healthcare Market Research Netherlands

    Netherlands healthcare research overview — HCP surveys, payer research, HEOR, and patient studies.

    Healthcare Market Research

    BioNixus global healthcare market research capabilities — HCP insights, KOL mapping, market access, and patient research.

    Plan Market Research in the Netherlands

    BioNixus delivers CBG-MEB-aligned, ethics-compliant pharmaceutical and healthcare market research across the Netherlands — HCP surveys at major academic medical centres, KOL mapping, Zorginstituut Nederland payer research, and HEOR evidence generation. Global standards. In-market Dutch execution.

    Request a Proposal View Dutch Research Capabilities
    Request a proposal